We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

71 hedge funds and large institutions have $159M invested in Spyre Therapeutics in 2019 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 6

108% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 12

100% more funds holding in top 10

Funds holding in top 10: 2 → 4 (+2)

29% more capital invested

Capital invested by funds: $123M → $159M (+$36.1M)

18% more funds holding

Funds holding: 60 → 71 (+11)

0% more ownership

Funds ownership: 2.74% → 2.74% (+0%)

Holders
71
Holders Change
+11
Holders Change %
+18.33%
% of All Funds
1.54%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.09%
New
17
Increased
25
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
+$4.17M
2
Goldman Sachs
Goldman Sachs
New York
+$3.22M
3
Marshall Wace
Marshall Wace
United Kingdom
+$3.13M
4
SFM
Sphera Funds Management
Israel
+$3.13M
5
ACM
Aisling Capital Management
New York
+$2.94M

Top Sellers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
-$4.8M
2
Man Group
Man Group
United Kingdom
-$286K
3
Squarepoint
Squarepoint
New York
-$173K
4
Morgan Stanley
Morgan Stanley
New York
-$152K
5
TI
Trexquant Investment
Connecticut
-$116K
Name Holding Trade Value Shares
Change 		Change in
Stake
Assenagon Asset Management
26
Assenagon Asset Management
Luxembourg
$757K +$784K +3,761 New
Man Group
27
Man Group
United Kingdom
$725K -$286K -1,372 -28%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$495K +$100K +481 +24%
Charles Schwab
29
Charles Schwab
California
$359K +$27.9K +134 +8%
UBS Group
30
UBS Group
Switzerland
$339K -$4.38K -21 -1%
Wells Fargo
31
Wells Fargo
California
$326K +$11.7K +56 +4%
Squarepoint
32
Squarepoint
New York
$312K -$173K -828 -35%
DAM
33
Deltec Asset Management
New York
$308K – – –
FSA
34
Franklin Street Advisors
North Carolina
$242K +$83.4K +400 +50%
TA
35
Teachers Advisors
New York
$238K – – –
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$238K +$31.5K +151 +15%
AQR Capital Management
37
AQR Capital Management
Connecticut
$228K – – –
William Blair & Company
38
William Blair & Company
Illinois
$219K – – –
RhumbLine Advisers
39
RhumbLine Advisers
Massachusetts
$194K +$21.3K +102 +12%
Deutsche Bank
40
Deutsche Bank
Germany
$183K +$30.4K +146 +19%
LF
41
Lee Financial
Texas
$180K – – –
MWNA
42
Marshall Wace North America
New York
$179K +$186K +892 New
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$174K +$40.9K +196 +29%
TCIM
44
TIAA CREF Investment Management
New York
$152K – – –
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$152K +$158K +756 New
AG
46
Algert Global
California
$148K -$61.1K -293 -29%
OAM
47
Oxford Asset Management
United Kingdom
$134K +$139K +665 New
Millennium Management
48
Millennium Management
New York
$117K -$52.9K -254 -30%
Bank of America
49
Bank of America
North Carolina
$111K -$28.8K -138 -20%
SAM
50
Sectoral Asset Management
Quebec, Canada
$104K – – –
1
2
3 4

SYRE Hedge Fund Activity: Q1 2019 in Review

71 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q1 2019, worth a combined $159M — up 29% from $123M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new SYRE positions and 6 closed out — a net gain of 11 holders — while 25 added to existing stakes and 12 trimmed.

The largest buyer was Deerfield Management, opening a new position worth an estimated $4.17M. The largest seller was Jennison Associates, cutting an estimated $4.8M.

  • 71 institutional investors held Spyre Therapeutics (SYRE) as of Q1 2019, up from 60 in Q4 2018.
  • Funds reported $159M of Spyre Therapeutics stock for Q1 2019, up 29% quarter-over-quarter.
  • 17 funds opened new Spyre Therapeutics positions in Q1 2019 and 6 closed out, a net change of +11 holders.
  • The largest Spyre Therapeutics buyer in Q1 2019 was Deerfield Management, an estimated $4.17M added.
  • The largest Spyre Therapeutics seller in Q1 2019 was Jennison Associates, an estimated $4.8M sold.

Based on aggregated 13F filings for Q1 2019.